Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China
Crossref DOI link: https://doi.org/10.1186/s12962-025-00643-7
Published Online: 2025-07-22
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Yueyang
Yuan, Hongmei
Huang, Zhe
Text and Data Mining valid from 2025-07-22
Version of Record valid from 2025-07-22
Article History
Received: 9 March 2024
Accepted: 27 June 2025
First Online: 22 July 2025
Declarations
:
: Not applicable.
: The authors declare no competing interests.